MediWound Ltd. announced the appointment of Ofer Gonen as Chief Executive Officer (CEO) of MediWound as of June 30, 2022, succeeding Sharon Malka. Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries Ltd. (“CBI”), MediWound's largest shareholder, for the past 5 years. Ofer Gonen will assume the role of the Chief Executive Officer after serving as the CEO of Clal Biotechnology Industries Ltd. (TASE: CBI) and Cactus Acquisition Corp.

1 (Nasdaq: CCTS). He has more than 20 years of experience in managing life science investments and global business collaborations. Mr. Gonen serves as a board member of several publicly-traded biopharmaceutical technology companies, including, Gamida Cell (Nasdaq: GMDA), MediWound (Nasdaq: MDWD) and Cactus (Nasdaq: CCTS), as well as a managing partner at the Anatomy Medical Fund.

Prior to joining CBI, he was the General Manager of Biomedical Investments Ltd., and the founder and Managing Partner at Arte Venture Group. Mr. Gonen is a strong business development professional, skilled in entrepreneurship, global strategic partnerships, IPOs, licensing deals, and M&A transactions. He holds a B.Sc.

in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction.